Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention
Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful developm...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Lemon, Stanley M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
18 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of the antigenic region of - Abdelbaky, Hanan H. ELSEVIER, 2018, official journal of the European Association for the Study of the Liver, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:68 ; year:2018 ; number:1 ; pages:167-184 ; extent:18 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jhep.2017.08.034 |
|---|
| Katalog-ID: |
ELV041435583 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV041435583 | ||
| 003 | DE-627 | ||
| 005 | 20230625234605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2017.08.034 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000353.pica |
| 035 | |a (DE-627)ELV041435583 | ||
| 035 | |a (ELSEVIER)S0168-8278(17)32278-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Lemon, Stanley M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 18 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. | ||
| 520 | |a Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. | ||
| 650 | 7 | |a Prevention |2 Elsevier | |
| 650 | 7 | |a Molecular virology |2 Elsevier | |
| 650 | 7 | |a Hepatitis A virus |2 Elsevier | |
| 650 | 7 | |a Prevalence |2 Elsevier | |
| 650 | 7 | |a Vaccine |2 Elsevier | |
| 650 | 7 | |a Epidemiology |2 Elsevier | |
| 700 | 1 | |a Ott, Jördis J. |4 oth | |
| 700 | 1 | |a Van Damme, Pierre |4 oth | |
| 700 | 1 | |a Shouval, Daniel |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Abdelbaky, Hanan H. ELSEVIER |t Identification of the antigenic region of |d 2018 |d official journal of the European Association for the Study of the Liver |g Amsterdam [u.a.] |w (DE-627)ELV000433829 |
| 773 | 1 | 8 | |g volume:68 |g year:2018 |g number:1 |g pages:167-184 |g extent:18 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jhep.2017.08.034 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 68 |j 2018 |e 1 |h 167-184 |g 18 | ||
| author_variant |
s m l sm sml |
|---|---|
| matchkey_str |
lemonstanleymottjrdisjvandammepierreshou:2018----:yevrleaiiaumradpaenhmlclriooypdmoo |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
44.44 |
| publishDate |
2018 |
| allfields |
10.1016/j.jhep.2017.08.034 doi GBV00000000000353.pica (DE-627)ELV041435583 (ELSEVIER)S0168-8278(17)32278-X DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Lemon, Stanley M. verfasserin aut Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention 2018transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology Elsevier Ott, Jördis J. oth Van Damme, Pierre oth Shouval, Daniel oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:68 year:2018 number:1 pages:167-184 extent:18 https://doi.org/10.1016/j.jhep.2017.08.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 68 2018 1 167-184 18 |
| spelling |
10.1016/j.jhep.2017.08.034 doi GBV00000000000353.pica (DE-627)ELV041435583 (ELSEVIER)S0168-8278(17)32278-X DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Lemon, Stanley M. verfasserin aut Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention 2018transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology Elsevier Ott, Jördis J. oth Van Damme, Pierre oth Shouval, Daniel oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:68 year:2018 number:1 pages:167-184 extent:18 https://doi.org/10.1016/j.jhep.2017.08.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 68 2018 1 167-184 18 |
| allfields_unstemmed |
10.1016/j.jhep.2017.08.034 doi GBV00000000000353.pica (DE-627)ELV041435583 (ELSEVIER)S0168-8278(17)32278-X DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Lemon, Stanley M. verfasserin aut Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention 2018transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology Elsevier Ott, Jördis J. oth Van Damme, Pierre oth Shouval, Daniel oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:68 year:2018 number:1 pages:167-184 extent:18 https://doi.org/10.1016/j.jhep.2017.08.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 68 2018 1 167-184 18 |
| allfieldsGer |
10.1016/j.jhep.2017.08.034 doi GBV00000000000353.pica (DE-627)ELV041435583 (ELSEVIER)S0168-8278(17)32278-X DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Lemon, Stanley M. verfasserin aut Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention 2018transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology Elsevier Ott, Jördis J. oth Van Damme, Pierre oth Shouval, Daniel oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:68 year:2018 number:1 pages:167-184 extent:18 https://doi.org/10.1016/j.jhep.2017.08.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 68 2018 1 167-184 18 |
| allfieldsSound |
10.1016/j.jhep.2017.08.034 doi GBV00000000000353.pica (DE-627)ELV041435583 (ELSEVIER)S0168-8278(17)32278-X DE-627 ger DE-627 rakwb eng 610 VZ 44.44 bkl Lemon, Stanley M. verfasserin aut Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention 2018transfer abstract 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology Elsevier Ott, Jördis J. oth Van Damme, Pierre oth Shouval, Daniel oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:68 year:2018 number:1 pages:167-184 extent:18 https://doi.org/10.1016/j.jhep.2017.08.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 68 2018 1 167-184 18 |
| language |
English |
| source |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:68 year:2018 number:1 pages:167-184 extent:18 |
| sourceStr |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:68 year:2018 number:1 pages:167-184 extent:18 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| topic_facet |
Prevention Molecular virology Hepatitis A virus Prevalence Vaccine Epidemiology |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of the antigenic region of |
| authorswithroles_txt_mv |
Lemon, Stanley M. @@aut@@ Ott, Jördis J. @@oth@@ Van Damme, Pierre @@oth@@ Shouval, Daniel @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000433829 |
| dewey-sort |
3610 |
| id |
ELV041435583 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041435583</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625234605.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2017.08.034</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000353.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041435583</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(17)32278-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lemon, Stanley M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prevention</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular virology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatitis A virus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prevalence</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ott, Jördis J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Damme, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shouval, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:68</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:167-184</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2017.08.034</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">68</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">167-184</subfield><subfield code="g">18</subfield></datafield></record></collection>
|
| author |
Lemon, Stanley M. |
| spellingShingle |
Lemon, Stanley M. ddc 610 bkl 44.44 Elsevier Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention |
| authorStr |
Lemon, Stanley M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000433829 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.44 bkl Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology Elsevier |
| topic |
ddc 610 bkl 44.44 Elsevier Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology |
| topic_unstemmed |
ddc 610 bkl 44.44 Elsevier Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology |
| topic_browse |
ddc 610 bkl 44.44 Elsevier Prevention Elsevier Molecular virology Elsevier Hepatitis A virus Elsevier Prevalence Elsevier Vaccine Elsevier Epidemiology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j j o jj jjo d p v dp dpv d s ds |
| hierarchy_parent_title |
Identification of the antigenic region of |
| hierarchy_parent_id |
ELV000433829 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Identification of the antigenic region of |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000433829 |
| title |
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention |
| ctrlnum |
(DE-627)ELV041435583 (ELSEVIER)S0168-8278(17)32278-X |
| title_full |
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention |
| author_sort |
Lemon, Stanley M. |
| journal |
Identification of the antigenic region of |
| journalStr |
Identification of the antigenic region of |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
167 |
| author_browse |
Lemon, Stanley M. |
| container_volume |
68 |
| physical |
18 |
| class |
610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Lemon, Stanley M. |
| doi_str_mv |
10.1016/j.jhep.2017.08.034 |
| dewey-full |
610 |
| title_sort |
type a viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention |
| title_auth |
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention |
| abstract |
Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. |
| abstractGer |
Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. |
| abstract_unstemmed |
Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention |
| url |
https://doi.org/10.1016/j.jhep.2017.08.034 |
| remote_bool |
true |
| author2 |
Ott, Jördis J. Van Damme, Pierre Shouval, Daniel |
| author2Str |
Ott, Jördis J. Van Damme, Pierre Shouval, Daniel |
| ppnlink |
ELV000433829 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.jhep.2017.08.034 |
| up_date |
2024-07-06T20:06:45.764Z |
| _version_ |
1803861523971440640 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041435583</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625234605.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2017.08.034</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000353.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041435583</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(17)32278-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lemon, Stanley M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although epidemic jaundice was well known to physicians of antiquity, it is only in recent years that medical science has begun to unravel the origins of hepatitis A virus (HAV) and the unique pathobiology underlying acute hepatitis A in humans. Improvements in sanitation and the successful development of highly efficacious vaccines have markedly reduced the worldwide occurence of this enterically-transmitted infection over the past quarter century, yet the virus persists in vulnerable populations and those without HAV immunity and remains a common cause of food-borne disease outbreaks in economically-advantaged societies. Reductions in HAV incidence have led to increases in the median age at which infection occurs, often resulting in more severe disease in affected persons and paradoxical increases in disease burden in some developing nations. Here, we summarize recent advances in the molecular virology and epidemiology of HAV, an atypical member of the Picornaviridae family, survey what is known of the pathogenesis of hepatitis A in humans and the host-pathogen interactions that typify the infection. The article also reviews medical and public health aspects of HAV vaccination and disease prevention.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prevention</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Molecular virology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatitis A virus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prevalence</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ott, Jördis J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Damme, Pierre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shouval, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:68</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:167-184</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2017.08.034</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">68</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">167-184</subfield><subfield code="g">18</subfield></datafield></record></collection>
|
| score |
7.3981857 |